Literature DB >> 22190310

Pain in patients with myotonic dystrophy type 2: a postal survey in Finland.

Kimmo I Suokas1, Maija Haanpää, Hannu Kautiainen, Bjarne Udd, Aki J Hietaharju.   

Abstract

INTRODUCTION: Widespread musculoskeletal pain is a well-known symptom of myotonic dystrophy type 2 (DM2), but so far it has been addressed in only a few studies.
METHODS: A postal survey for all traceable DM2 patients (n = 132) was conducted. A specific questionnaire, and severity and interference subscales of the Brief Pain Inventory, quality of life (RAND-36), and modified Beck Depression Inventory were completed.
RESULTS: The response rate was 70%. The mean age of respondents was 53 years, 59% of whom were women. Current pain was reported by 54%. Lifetime prevalence of pain was 76%. The mean intensity of pain at its highest in the last week was 5.9, and 2.3 at its lowest (on a numerical rating scale of 0-10). Quality of life was lower in DM2 patients who reported pain. In 18%, the depression score was noticeably different.
CONCLUSIONS: Pain of moderate severity and unpleasant muscular symptoms are common in DM2. DM2 should be taken into consideration in the differential diagnosis of musculoskeletal pain.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22190310     DOI: 10.1002/mus.22249

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  17 in total

1.  Validity of three rating scales for measuring pain intensity in youths with physical disabilities.

Authors:  J Miró; E Castarlenas; R de la Vega; E Solé; C Tomé-Pires; M P Jensen; J M Engel; M Racine
Journal:  Eur J Pain       Date:  2015-03-31       Impact factor: 3.931

2.  Diagnostic odyssey of patients with myotonic dystrophy.

Authors:  James E Hilbert; Tetsuo Ashizawa; John W Day; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

3.  Summary of Selected Healthcare Encounters among a Selection of Patients with Myotonic Muscular Dystrophy.

Authors:  Kevin J Bennett; Joshua R Mann; Lijing Ouyang
Journal:  South Med J       Date:  2019-06       Impact factor: 0.954

Review 4.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

Review 5.  Sleep Complaints, Sleep and Breathing Disorders in Myotonic Dystrophy Type 2.

Authors:  Andrea Romigi; Michelangelo Maestri; Carmine Nicoletta; Giuseppe Vitrani; Marco Caccamo; Gabriele Siciliano; Enrica Bonanni; Diego Centonze; Alessandro Sanduzzi
Journal:  Curr Neurol Neurosci Rep       Date:  2019-02-09       Impact factor: 5.081

Review 6.  Biomolecular diagnosis of myotonic dystrophy type 2: a challenging approach.

Authors:  Giovanni Meola; Fiammetta Biasini; Rea Valaperta; Elena Costa; Rosanna Cardani
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

Review 7.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

Review 8.  Chronic pain in neuromuscular disease: pain site and intensity differentially impacts function.

Authors:  Jordi Miró; Kevin J Gertz; Gregory T Carter; Mark P Jensen
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-10-17       Impact factor: 1.784

9.  Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Authors:  Chad Heatwole; Nicholas Johnson; Rita Bode; Jeanne Dekdebrun; Nuran Dilek; James E Hilbert; Elizabeth Luebbe; William Martens; Michael P McDermott; Christine Quinn; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

10.  Characteristics of pain in amyotrophic lateral sclerosis.

Authors:  Frank Hanisch; Anika Skudlarek; Janine Berndt; Malte E Kornhuber
Journal:  Brain Behav       Date:  2015-01-21       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.